Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Company Overview

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Key Stats

• Today's Range: $0.44 to $0.48
• 50-Day Range: $0.34 to $0.80
• 52-Week Range: $0.30 to $4.28
• Volume: 1.23 million shs
• Average Volume: 2.29 million shs
• Market Capitalization: $30.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.20
• Consensus Rating: Buy

Reviva Pharmaceuticals Stock Analysis - MarketRank™

Reviva Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 521st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Reviva Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.97) to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Reviva Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Reviva Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Reviva Pharmaceuticals has a P/B Ratio of 22.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

34.18% of the float of Reviva Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Reviva Pharmaceuticals has recently increased by 97.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Reviva Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Reviva Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

34.18% of the float of Reviva Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Reviva Pharmaceuticals has recently increased by 97.52%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.93

News Sentiment

Reviva Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.11 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 19 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.

MarketBeat Follows

13 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RVPH Stock Analysis - Frequently Asked Questions

How have RVPH shares performed this year?

Reviva Pharmaceuticals' stock was trading at $1.81 at the beginning of the year. Since then, RVPH shares have decreased by 75.1% and is now trading at $0.45.

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) released its quarterly earnings data on Thursday, August, 14th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03.

Who are Reviva Pharmaceuticals' major shareholders?

Reviva Pharmaceuticals' top institutional investors include Armistice Capital LLC (5.61%), 683 Capital Management LLC (2.08%), Persistent Asset Partners Ltd (1.34%) and Geode Capital Management LLC (0.93%). Insiders that own company stock include Prabhu Narayan and Purav Patel.
View institutional ownership trends.

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Reviva Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/01/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RVPH
• CIK: 1742927
• Web: www.revivapharma.com
• Phone: (408) 501-8881
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Reviva Pharmaceuticals: $5.20
• High Price Target: $11.00
• Low Price Target: $2.00
• Potential Upside/Downside: +1,055.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -259.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.90
• Quick Ratio: 0.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 22.50

Miscellaneous

• Outstanding Shares: 68,004,000
• Free Float: 49,521,000
• Market Cap: $30.60 million
• Optionable: Optionable
• Beta: -0.04